BIOMAT Database Logo BIOMAT Database Logo

Coexistence of anti-glomerular basement membrane antibodies and myeloperoxidase-ANCAs in crescentic glomerulonephritis. 2005

Abraham Rutgers, and Marjan Slot, and Pieter van Paassen, and Peter van Breda Vriesman, and Peter Heeringa, and Jan Willem Cohen Tervaert
Department of Clinical and Experimental Immunology, Cardiovascular Research Institute Maastricht, Maastricht University, The Netherlands.

BACKGROUND In a substantial proportion of patients with crescentic glomerulonephritis (CGN), both anti-glomerular basement membrane (GBM) antibodies and antineutrophil cytoplasmic antibodies (ANCAs) with specificity for myeloperoxidase (MPO-ANCA) are detected. In the present study, we questioned whether histological and clinical features of patients with both ANCA and anti-GBM antibodies differ from those of patients with either ANCA or anti-GBM alone. METHODS We reviewed the Limburg renal biopsy registry (1978 to 2003; n = 1,373) for cases of CGN. The presence of linear fluorescence on renal biopsy and the presence of ANCA and/or anti-GBM antibodies were measured. Subsequently, we assessed patient characteristics and follow-up and compared histological findings among the different groups. RESULTS We identified 46 MPO-ANCA-positive, 10 double-positive, and 13 anti-GBM-positive patients. Mean ages were 63, 64, and 52 years (P = 0.04), and serum creatinine levels were 5.0, 10.3, and 9.6 mg/dL (445, 910, and 850 micromol/L), respectively (P = 0.01). Granulomatous periglomerular inflammation was found in either MPO-ANCA- or double-positive patients, but not in anti-GBM-positive patients with CGN without MPO-ANCAs. Patient survival among the 3 groups was different, although not statistically significant (log rank P = 0.17, with 75%, 79%, and 100% alive at 1 year, respectively). Renal survival analysis showed significant differences among the 3 groups (P = 0.04, with 65%, 10%, and 15% off dialysis therapy at 1 year, respectively). CONCLUSIONS In patients with both anti-GBM antibodies and MPO-ANCAs, histological findings differ from those of patients with anti-GBM antibodies only. However, renal survival in these patients is not better than that in anti-GBM-positive patients and is worse compared with patients with MPO-ANCAs only.

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D007678 Kidney Glomerulus A cluster of convoluted capillaries beginning at each nephric tubule in the kidney and held together by connective tissue. Glomerulus, Kidney
D008297 Male Males
D008565 Membrane Proteins Proteins which are found in membranes including cellular and intracellular membranes. They consist of two types, peripheral and integral proteins. They include most membrane-associated enzymes, antigenic proteins, transport proteins, and drug, hormone, and lectin receptors. Cell Membrane Protein,Cell Membrane Proteins,Cell Surface Protein,Cell Surface Proteins,Integral Membrane Proteins,Membrane-Associated Protein,Surface Protein,Surface Proteins,Integral Membrane Protein,Membrane Protein,Membrane-Associated Proteins,Membrane Associated Protein,Membrane Associated Proteins,Membrane Protein, Cell,Membrane Protein, Integral,Membrane Proteins, Integral,Protein, Cell Membrane,Protein, Cell Surface,Protein, Integral Membrane,Protein, Membrane,Protein, Membrane-Associated,Protein, Surface,Proteins, Cell Membrane,Proteins, Cell Surface,Proteins, Integral Membrane,Proteins, Membrane,Proteins, Membrane-Associated,Proteins, Surface,Surface Protein, Cell
D008856 Microscopy, Fluorescence Microscopy of specimens stained with fluorescent dye (usually fluorescein isothiocyanate) or of naturally fluorescent materials, which emit light when exposed to ultraviolet or blue light. Immunofluorescence microscopy utilizes antibodies that are labeled with fluorescent dye. Fluorescence Microscopy,Immunofluorescence Microscopy,Microscopy, Immunofluorescence,Fluorescence Microscopies,Immunofluorescence Microscopies,Microscopies, Fluorescence,Microscopies, Immunofluorescence
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009195 Peroxidase A hemeprotein from leukocytes. Deficiency of this enzyme leads to a hereditary disorder coupled with disseminated moniliasis. It catalyzes the conversion of a donor and peroxide to an oxidized donor and water. EC 1.11.1.7. Myeloperoxidase,Hemi-Myeloperoxidase,Hemi Myeloperoxidase
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D003404 Creatinine Creatinine Sulfate Salt,Krebiozen,Salt, Creatinine Sulfate,Sulfate Salt, Creatinine

Related Publications

Abraham Rutgers, and Marjan Slot, and Pieter van Paassen, and Peter van Breda Vriesman, and Peter Heeringa, and Jan Willem Cohen Tervaert
Seronegative atypical anti-glomerular basement membrane crescentic glomerulonephritis.
June 2019, Annals of translational medicine,
Abraham Rutgers, and Marjan Slot, and Pieter van Paassen, and Peter van Breda Vriesman, and Peter Heeringa, and Jan Willem Cohen Tervaert
Educational Case: Necrotizing and Crescentic Glomerulonephritis With Anti-Glomerular Basement Membrane Antibodies (Anti-Gbm).
January 2020, Academic pathology,
Abraham Rutgers, and Marjan Slot, and Pieter van Paassen, and Peter van Breda Vriesman, and Peter Heeringa, and Jan Willem Cohen Tervaert
Relapse in anti glomerular basement membrane antibody mediated crescentic glomerulonephritis.
February 1980, Clinical nephrology,
Abraham Rutgers, and Marjan Slot, and Pieter van Paassen, and Peter van Breda Vriesman, and Peter Heeringa, and Jan Willem Cohen Tervaert
Anti-myeloperoxidase antibodies in crescentic glomerulonephritis.
January 1991, Nephron,
Abraham Rutgers, and Marjan Slot, and Pieter van Paassen, and Peter van Breda Vriesman, and Peter Heeringa, and Jan Willem Cohen Tervaert
Combined membranous nephropathy and crescentic glomerulonephritis with concurrent anti-glomerular basement membrane antibody and myeloperoxidase-specific anti-neutrophil cytoplasmic antibody.
May 2013, CEN case reports,
Abraham Rutgers, and Marjan Slot, and Pieter van Paassen, and Peter van Breda Vriesman, and Peter Heeringa, and Jan Willem Cohen Tervaert
Presence of Anti-Glomerular Basement Membrane Antibodies and Myeloperoxidase Anti-Neutrophilic Cytoplasmic Antibodies in a Case of Rapidly Progressive Glomerulonephritis.
January 2015, Frontiers in medicine,
Abraham Rutgers, and Marjan Slot, and Pieter van Paassen, and Peter van Breda Vriesman, and Peter Heeringa, and Jan Willem Cohen Tervaert
Matrix metalloproteinase-12 deficiency attenuates experimental crescentic anti-glomerular basement membrane glomerulonephritis.
February 2018, Nephrology (Carlton, Vic.),
Abraham Rutgers, and Marjan Slot, and Pieter van Paassen, and Peter van Breda Vriesman, and Peter Heeringa, and Jan Willem Cohen Tervaert
[An experience of treatment of double positive myeloperoxidase-antineutrophil cytoplasmic antibodies (MPO-ANCA) and anti-glomerular basement membrane antibodies in Goodpasture's syndrome onset of crescentic glomerulonephritis].
November 1998, Nihon Jinzo Gakkai shi,
Abraham Rutgers, and Marjan Slot, and Pieter van Paassen, and Peter van Breda Vriesman, and Peter Heeringa, and Jan Willem Cohen Tervaert
Anti-Glomerular Basement Membrane Glomerulonephritis.
November 2023, The New England journal of medicine,
Abraham Rutgers, and Marjan Slot, and Pieter van Paassen, and Peter van Breda Vriesman, and Peter Heeringa, and Jan Willem Cohen Tervaert
A Case Report of Crescentic Glomerulonephritis With Positive Serum Anti-glomerular Basement Membrane Without Linear Glomerular Basement Membrane Immunofluorescent Staining.
May 2022, Cureus,
Copied contents to your clipboard!